Overview

• Valneva said the suspension takes effect immediately and halts all Ixchiq shipments and sales in the United States.
• The newly reported U.S. cases involve four recipients ages 55 to 82, which the company described as comparable to previously known events.
• During a major spring outbreak in La Réunion, about twenty serious adverse events were recorded among older vaccine recipients and one death was deemed very likely linked.
• Regulatory positions now diverge as the European Union reauthorized the shot in July after earlier age-based limits, while France had restricted use in seniors.
• Valneva is evaluating potential financial impacts of a prolonged U.S. withdrawal as some researchers voice concern about a broader shift toward vaccine skepticism under Health Secretary Robert Kennedy Jr.